Member Info for countingcards

Graham Duncan has considerable international experience, including four years in Hong Kong where he advised on corporate transactions in the Asia Pacific region.

Ciali de Jager Finance Manager East Imperial - Premium Tonic Waters & Mixers

Nov 2022 - Nov 2023 1 year 1 month

Auckland, New Zealand

I see the £325k as a seperate placing requirement and not connected to the previous raise. You have to make it look rather bland to shake a few out before actually releasing the main news!

The last known figure I had for Aviva Investor Global services Ltd was 11,792,010 or 3.49% back from late 2022. So today they hold 8.52% which is a change of 5.03% . They have a holding of 31,322,325. So at some point they have sold a small amount of around 1.5m for whatever reasons between 2022-2023. The holding remains under the same holding name. They are the 2nd largest holders after Anthony Burt who owns, 17.28% as of today, and other significant holders are, Life Force investments Ltd with 5.98% a drop as they sold 823,512 shares. Micheal Dawson also a significant holder at 5.14%.

Https://www.londonstockexchange.com/news-article/EISB/holding-s-in-company/16310981

Sorry for the long post.

I am more focused on current partnership going on here

1.Wen Hua International ("WHI"), the Company's current Chinese Mainland and Macau distribution partner (the "Proposed Transaction").

The Company and WHI, through its wholly owned Hong-Kong based subsidiary, INL Investment Limited, has today entered into a Conditional Loan Note Subscription Agreement ( " Subscription Agreement " ) pursuant to which WHI has agreed to invest GBP2,200,000 in two tranches of GBP1,466,666. 67 ( " Tranche 1 " ) and GBP733,333.33 ( " Tranche 2 " ) respectively, conditional on the passing of the Resolutions by Shareholders at the General Meeting by 31 August 2023 (or such later date as agreed by the Company and WHI).

Proposed issue of GBP2.2 million of 10% Secured Convertible Loan Notes to strategic investor WHI in two tranches of GBP1,466,666.67 and GBP733,333.33 respectively.

The 2025 Convertible Loan Notes will be secured by way of a debenture which contains fixed and floating charges over the assets of the Company; security to be granted over the Company's wholly owned Singapore incorporated subsidiary; and a charge to be granted over up to 75 per cent. of the ordinary shares of GBP0.01 each in the capital of the Company ("Ordinary Shares") held by the Company's chief executive officer, Tony Burt.

Jason Ieong, CEO of WHI, said:

"Being a leading distributor of Imported Spirits & Wines in China, we are excited to extend our business relationship with East Imperial, the global purveyor of ultra-premium beverages. With our support, we believe East Imperial will be able to fast-track its global development in all strategic markets and capitalize the premiumization trend in the beverage category globally”.

2.In the meantime, David Dawson increased his holding from 0% to 5.58% from Aug 2023 to Dec 2023

3.Alistair McGeorge stepped down as Chairman and Non-Executive Director of the Company, effective 10 November 2023. “CEO and Founder Tony Burt will act as Executive Chairman until an independent Chair with the appropriate industry expertise has been identified and appointed.”

4. Allenby came in from Dec 2023. From their site ”Allenby Capital is a leading adviser and broker to rapidly growing businesses seeking to access private or public equity capital” Also on same site Broker offering a variety of funding solutions for fast growing companies.”

So, here the main quotes used are “fast-track” “rapidly growing” “fast growing” EISB are deploying cash at such a fast rate that current expansion needs more cash. Around April 2023 we will get to know more.

Who took 8%? Those shares go live in 4 days so we should know unless they go below the 3% and do not need to disclose.

I am happy the wording of the last RNS on reading again caused concern within the weaker small holders.

Confident on where this is heading. Short term turbulence for long term gain

I am hoping so as well m007j, that the buyer is long term and not going to sell into the market.

Also remember from 07.11.2023: The Company has also granted INL Investment Limited security over the Company's wholly owned Singapore incorporated subsidiary and Tony Burt, the Company's chief executive officer, has granted a charge over 47,645,448 ordinary shares of GBP0.01 each in the capital of the Company held by him representing 14.1 per cent. of the issued share capital.

Tony Burt has a charge over his 14.1%. Its therefore in his interest to get things clearer.

"The Placing Shares have been placed exclusively with one investor"

If that being the case the shares admission will become effective and that dealings in the Placing Shares will commence at 8.00 a.m. on or around 29 January 2024.

If these are going to be held, then I expect a holding RNS for 8.03%. If not then I expect the price to rise and be sold into by the new investor otherwise right now they will be holding at a loss.

To think I was going to add yesterday and was distracted. The opportunity to add at a much lower price this morning was there so took it. Although I say opportunity, not happy with time delays, but you with it out of no choice, and when I saw Allenby had been added a while back I can see my 'uh oh' instinct was correct and the placing this morning proved it. Another side of me though this had to do with shipping costs rising but it seems our channels are far removed to what is happening.

Not a good start here this morning.

Are you a shareholder in those organisations?

No

The National Institutes of Health, American cancer Society, Cancer Research UK, are just three different organisations and institutes who have the same information on their sites or near similar. Are they also just being pointless?

Https://www.londonstockexchange.com/news-article/OCTP/patent-applications/16282243

https://*************.net/what-is-east-imperials-secret-weapon

Https://www.tasteradio.com/episodes/2023/east-imperials-secret-weapon-a-consistent-disciplined-emphasis-on-this/

Https://www.sec.gov/Archives/edgar/data/1896212/000149315223045267/form424b3.htm

Https://www.londonstockexchange.com/news-article/EISB/appointment-of-allenby-capital-as-broker/16243761

RNS Number : 1008W

East Imperial PLC

08 December 2023

8 December 2023

East Imperial plc

(the "Company")

Appointment of Allenby Capital as Broker

East Imperial plc, the global purveyor of super-premium beverages, is pleased to announce the appointment of Allenby Capital Limited as the Company's sole Broker, with immediate effect.

The appointment aligns with the Company's strategy of expanding the group's investor base as it continues to establish itself as the producer of super-premium beverages across APAC, the US and EMEA.

Tony Burt, Chairman, Founder and CEO of East Imperial, said:

"We are very pleased to be embarking on a long-term partnership with Allenby Capital as our Broker. They deeply understand the consumer retail and hospitality sector, particularly within the growth company space. Their experience in helping ambitious companies grow will be invaluable to East Imperial as we expand in premium markets worldwide. This is an important milestone in our strategy to become the most admired premium brand of mixers and drive sustainable growth to create value for our shareholders."

Allenby Capital is a leading corporate adviser and broker advising over 70 corporate clients on the London Stock Exchange Main Market, AIM or Aquis exchanges. Based in London, it is employee owned and focuses on the small cap and growth company sectors, having a strong history of supporting the capital markets of its extensive client base.

Honestly Jace it cracks me up. People can put whatever checkout price they want on this, thats personal, but to tjhink Dr Dawn Coverley has been at this for over 15 years, and would be willing to sell out at 5 times RTO price? LOL

Like you mate here for the end game and that is far in excess to what others consider. Made my day! LOL

Today 07:00

RNS Number : 2956T

Oxford Cannabinoid Tech.Holdings

14 November 2023

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Directorate Appointment

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, announces the following Board appointment.

Reflecting his exceptional experience and valued contribution to the progress of OCTP, the Company is pleased to announce the appointment of Dr Tim Corn, Chief Medical Officer ("CMO"), as an executive director, effective immediately. As announced on 8 June 2023, Dr Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201.

Dr Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.

13 November 2023

East Imperial plc

(the "Company")

Directorship Changes

East Imperial plc, the global purveyor of ultra-premium beverages, today announces that Alistair McGeorge will step down as Chairman and Non-Executive Director of the Company, effective 10 November 2023.

Robin Stevens will join as a Non-Executive Director effective 10 November 2023. Robin brings a wealth of experience in corporate finance, financial advisory and business consulting. Currently, he is a Senior Adviser and Capital Markets Lead at MHA MacIntyre Hudson LLP, providing capital markets and corporate finance advice to firms in the UK and overseas. He has particular experience working with emerging companies in the Asia-Pacific region.

CEO and Founder Tony Burt will act as Executive Chairman until an independent Chair with the appropriate industry expertise has been identified and appointed.

Tony Burt, CEO/Founder, commented:

"I'd like to thank Alistair for his two years of service and wish him all the best for the future. I'm also delighted to welcome Robin, who brings extensive experience in corporate finance, PLC governance and emerging companies in the Asia-Pacific region. His knowledge of the City, insight and UK PLC experience will be a tremendous asset to us."

7:05 AM · Oct 31, 2023

Pullman Hotel Singapore

https://twitter.com/East_Imperial/status/1719249253824901564

(part 3)

For example I do know that Supermarkets are CONSTANTLY vying with one another even stores from within the same company. Notably, one NZ Supermarket stocks EISB then another follows suit. In the 2022 Annual Report: “Foodstuffs, New Zealand’s largest food retailer, extended our placement across 102 North Island stores. With this, we are now found in all New Worlds and their competitors, Countdown (110 stores), across the country.”

7. My final key assumption is margin. I assume we see 20% margin (i.e. the same as H1’s adjusted margin, i.e. no more written off stock), followed by 32% in 2024 (WH Ireland’s estimate) when “Management believes over time that a goal of a margin above 45% is achievable for a super-premium product.”

Investment Thesis

Should you invest? I don’t give advice. But giving myself some advice I’m happy to continue to hold here. Extremely happy I topped up and averaged down at 0.9p because I’m now back in profit. Will it survive its rocky past 12 months? - my numbers appear to say yes. Will there be dilution - again yes - but the nature of the scheme means as the share price rises the dilution diminishes. Currently it equates to about 10% dilution, which I’m more than happy with.

Could EISB be the next Fevertree? When you extrapolate to FY2025 things get very exciting. When you hit 45% margins, not 32% this becomes very profitable. Applying a 30X valuation to the FY2024 H2 adjusted profit arrives at a target value of £45m which is 5X today’s market cap. Doubling again in 2025 and applying 30X arrives at a 10 bagger - just like Fevertree.

A final thought:

Do you want to see East Imperial being sold online? Click here if you do

A Kiwi Dollar is $1 = £0.49 so a 10 pack is about £11 or £6.11 a litre.

Fevertree in Sainsburys is £8.25 and £4.71a litre.

So East Imperial is 25% more expensive. But award winning.

What about the Peter Lynch test…. only buy what you know. So it passes. I would pay extra for something that tasted that much nicer. Ironically, with Fevertree’s ditty of “when the tonic is 80% of the drink….” echoing in my head!

Have a great weekend reader, and thank you for reading the latest thoughts from the Oak Bloke.

(part2)

macau.

“with the strategic investment from inl investments, we will see a renewed focus on growing our position in china as the super-premium mixer for this market. the focus for q4 and q1 2024 will be macau, focusing on luxury accommodation and exquisite dining experiences to which our products are well suited.”

pre-covid there were 39m tourists a year spending us$40bn a year. while there are not macau alcohol statistics broadly in china spirits consumption is enormous worth us$166bn/year

so the “asian las vegas” where people go to have a great time, seems a great way to focus on growing sales.

forecasts:

key asumptions: (i’ve used the interim report and the 2022 annual report to obtain numbers)

1. i’ve calculated the price per case in 2021 was £13.51 and 2022 was £14.02. i’m using £14.02 for 2023 and 2024. this might be conservative. while case sales are not disclosed in the interims, i estimate at 89,642 cases for h1 2023 which is 22% less than 2022.

2. i’ve calculated the cost per case in 2021 was £10.91 and 2022 was £11.83. adjusted cost per case in h1 2023 i estimate at £11.76 which is highly consistent to h2 2022.

3. i’m conservatively assuming overheads are static despite eisb saying we “anticipate further efficiencies to help drive a lower operating cost base, including an incentive program tightly aligned to broader business targets”. tightly aligned means you get great commission but don’t expect a base salary bump :)

4. i’m not making any assumptions around other income, fx, just focused on operational outcome.

5. i’m assuming receivables remain low in h2 (i previously commented that they would run a tight ship on receivables) but inevitably rise next year. charging for fob basically means the money is due when it reaches the ship, not when it reaches the customer.

6. sales - i’m conservatively assuming +40% in h2 (89,642 cases) at £14.02/case. i’m doubling volumes in h1 2024 and doubling again in h2. this is a key assumption. but that equates to an additional 125k cases in h1 2024 and 250k cases in h2. with 12 bottles per case that’s equivalent to 1% in h1 then 2% in h2 of macau tourists enjoying just 4 bottles of east imperial mixers during a holiday. or the 1m ****tail courier recipients receiving 1 bottle each plus 0.4% then order a case in h1 and just a quarter of that 0.4% go on to order a case a week in h2 “coz, boss, yeah, this stuff is selling like hot cakes - and, yeah, let’s talk now about that tightly aligned incentive scheme we was talking about”. or air new zealand selling a single bottle to 1% of its 17m annual passengers and of those a third go on to buy a few cases. or some combination of the above plus everything else which is going on.

(cont'd)